Are you kidding me? This thing is the setting for every horror scenario set in the north/south polar regions. It's all shiny and futuristic until zombie snow monsters start to kill you.
@TheLostVikings R.O.A.C.H.: Apparently houses in my country suck then. Living in Edmonton, Alberta, Canada. Fancy ourselves relatively cold compared to the weather down south. Just don't care enough to actually get proper insulating apparently. Very jealous of your heating systems.
Two thoughts: 1) It's go much too high a profile and is likely to blow over in a storm. 2) It's got way too much glass to keep the interior at a comfortable temperature.
Looks pretty cool, though I'd add tracks all the way back, not just up front.
These seem like cool devices. I'm not clear on the advantage of performing reactions on a chip in the presence of an enzyme. It seems like you could make a library of compounds using combinatorial chemistry and then screen them using enzymes on a chip.
To address the some issues raised below, R+D costs are essentially negligible when bringing a drug to market. More money is spent in marketing a drug before it is even approved by the FDA than is spent on R+D. This chip would be only a tiny part of R+D.
Secondly, the analysis of the reaction products is not that hard. You run the product solution into the mass spec and measure the ratio of reaction substrates to reaction product. The only trick is to develop a valve system that controls the delivery of the reactions to the mass spec.
Third, the big use for these devices is their use in sensors that allow a small amount of sample (like blood) to be tested against a large panel of drugs. It could give you a deep view into a patients metabolic state, for example.
@Nick: mission accomplished:
"hurry up and wait"... Just curious, do you actually know anything about the FDA approval process for new drugs or are you just echoing what you've heard other say?
@Nick: mission accomplished: I'm pretty sure it has much ado with money changing hands.. sorta like how they screwed over a bunch of people by changing the albuterol inhalers so they work crap and cost 3x the price. Tell me there wasn't some profit margin at work there...
"Using microfluidics, the system may dramatically accelerate drug development for cancer and other diseases:"
...to reduce costs for drug companies, so they can get a new set of gold rims on their bentley golf carts.
@lpranal: I would imagine the opposite effect. Lower development costs and research time would enable smaller companies to penetrate (hehe penetrate) the market, driving down profits for large drug companies.
@Hello Mister Walrus: the optimistic part of me wants to believe that, but the bigger drug companies didn't get that way by letting the smaller guys get access to this stuff
@Hello Mister Walrus: Its not as much development costs as it is going through the clinical trials to get a drug FDA approved and actually to market. Hardly anyone besides BigPharma can pay for the phase II/III trials.
@Skeptics: It's reasonable to assume that any reduction in production time and, consequently, costs for producing new drugs would constitute a reduction in barriers to entry in the pharmaceutical industry. A device like this is obviously not going to change the whole industry by itself. However, incremental improvements like this might eventually enable smaller (though not necessarily small) companies to exist alongside Big Pharma.
Today, it might take 10 years and $100 million to create and market a new drug. Since only huge companies can put up such a large initial investment and wait that long to turn a profit, they dominate the industry. However, there must be a turning point at which smaller companies will be willing to enter the market. It might be 5 years and $50 million, or 2 years and $25 million - who knows? The point is, as drug development time and costs decrease, we get incrementally closer to that turning point.
09/17/09
Ok.. now where is the Mach 5
09/17/09
09/17/09
09/17/09
09/17/09
09/17/09
09/18/09
We have massive windows at my house, yet even when the snow reaches up to the 2nd story it's nice and warm inside.
09/19/09
09/17/09
09/17/09
Looks pretty cool, though I'd add tracks all the way back, not just up front.
09/17/09
09/17/09
09/17/09
09/17/09
08/04/09
To address the some issues raised below, R+D costs are essentially negligible when bringing a drug to market. More money is spent in marketing a drug before it is even approved by the FDA than is spent on R+D. This chip would be only a tiny part of R+D.
Secondly, the analysis of the reaction products is not that hard. You run the product solution into the mass spec and measure the ratio of reaction substrates to reaction product. The only trick is to develop a valve system that controls the delivery of the reactions to the mass spec.
Third, the big use for these devices is their use in sensors that allow a small amount of sample (like blood) to be tested against a large panel of drugs. It could give you a deep view into a patients metabolic state, for example.
08/04/09
08/04/09
08/04/09
"hurry up and wait"... Just curious, do you actually know anything about the FDA approval process for new drugs or are you just echoing what you've heard other say?
08/04/09
08/04/09
08/04/09
08/04/09
...to reduce costs for drug companies, so they can get a new set of gold rims on their bentley golf carts.
08/04/09
08/04/09
08/04/09
08/04/09
Today, it might take 10 years and $100 million to create and market a new drug. Since only huge companies can put up such a large initial investment and wait that long to turn a profit, they dominate the industry. However, there must be a turning point at which smaller companies will be willing to enter the market. It might be 5 years and $50 million, or 2 years and $25 million - who knows? The point is, as drug development time and costs decrease, we get incrementally closer to that turning point.